论文部分内容阅读
目的:通过研究抗酒石酸酸性磷酸酶(tartrate-resistant acid phosphatase,TRACP)在发生骨转移的前列腺癌患者血清中的变化,探讨其在前列腺癌发生骨转移过程中的临床意义。方法:以81例前列腺癌患者以及40例良性前列腺增生患者为研究对象,同时以40例健康青壮年男性作为对照,分为四组:前列腺癌骨转移患者组(A组,n=42),前列腺癌无骨转移患者组(B组,n=39),良性前列腺增生患者组(C组,n=40),健康对照组(D组,n=40)。应用双抗体夹心酶标免疫分析法测定患者血清标本中的TRACP水平,结合病理分级、Gleason评分、前列腺特异抗原(PSA)、碱性磷酸酶(ALP)、谷丙转氨酶(ALT)等进行统计学分析。结果:前列腺癌骨转移患者组的血清TRACP浓度明升高,与其他各组比较差异有统计学意义;血清TRACP浓度与PSA水平有较强的正相关性;ROC曲线下面积(AUC)均大于ALP和ALT,且TRACP与PSA的ROC曲线交叉,提示对骨转移的诊断价值较高。结论:TRACP的检测对于前列腺癌发生骨转移具有更直接的诊断价值和预测价值,通过监测前列腺癌患者的血清TRACP水平,对了解前列腺癌的生长状态、判断病程进展、预测骨转移的发生具有重要的临床意义。
OBJECTIVE: To investigate the clinical significance of tartrate-resistant acid phosphatase (TRACP) in the serum of prostate cancer patients with bone metastases and its clinical significance in the process of bone metastasis of prostate cancer. Methods: A total of 81 patients with prostate cancer and 40 patients with benign prostatic hyperplasia were enrolled in this study. Forty healthy young adults as controls were divided into four groups: group A (n = 42), patients with prostate cancer with bone metastasis Patients without prostate cancer (group B, n = 39), patients with benign prostatic hyperplasia (group C, n = 40), and healthy controls (group D, n = 40). The level of TRACP in serum of patients was determined by double antibody sandwich enzyme-linked immunosorbent assay. The pathological grade, Gleason score, prostate specific antigen (PSA), alkaline phosphatase (ALP) and alanine aminotransferase (ALT) analysis. Results: Serum TRACP concentration in patients with prostate cancer bone metastasis was significantly higher than that in other groups (P <0.05). There was a positive correlation between serum TRACP concentration and PSA level. The area under the curve of ROC (AUC) ALP and ALT, and TRACP and PSA ROC curve cross, suggesting that the diagnosis of bone metastasis is of high value. Conclusion: The detection of TRACP has a more direct diagnostic value and predictive value for the bone metastasis of prostate cancer. It is important to know the growth status of prostate cancer, to judge the progress of the disease and to predict the occurrence of bone metastasis by monitoring the level of serum TRACP in prostate cancer patients The clinical significance.